Evaluation of Activity & Clinical Efficacy of Novel Oral Probiotic Products

活动评价

• 批准号: 481623-2015
• 负责人: Douglas, Dan
• 金额: $ 10.39万
• 依托单位: Fanshawe College of Applied Arts & Technology
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 2
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=641715
• 关键词: Evaluation; Activity; Clinical; Efficacy; Novel

Oral/dental diseases -- primarily caused by infection by bacterial and fungal pathogens -- have been shown to contribute significantly to development of a number of systemic diseases. Despite increased spending on oral health products over the past decade, and the public perception of high standards of dental care, the rates of periodontal disease/gingivitis and cavities remain extremely high (60%-90%) across all age groups in Canada, the USA and internationally. Aside from brushing, dental cleaning and the use of antimicrobial products, there are currently few options available for maintaining a healthy mouth. Probiotic therapies are based on the concept of friendly bacteria interfering and competing with pathogens for space and nutrition at various body sites to restore the natural microflora balance, thereby reducing inflammation, tissue damage and other negative effects. Probiotics are quickly becoming increasingly acceptable and popular with medical professionals for the treatment of numerous disorders including digestive tract ailments and ear, nose and throat infections. Integra Medical Inc. of London, ON focuses on developing novel probiotic products with scientifically and clinically proven health benefits. The company currently has two oral care probiotic products (LorodentTM and KariodentTM) undergoing clinical assessment and plans to launch new products over the next five years in several additional areas including urology and bone/joint health. Integra will work with Fanshawe College's Dr. Peter Cadieux, a leading expert in the probiotic field, alongside Fanshawe co-op students from the Science Laboratory Technology diploma program and Bachelor of Applied Technology (Biotechnology) degree program to conduct rigorous scientific analyses of samples obtained from multiple clinical trials in order to evaluate the efficacy of Lorodent and Kariodent to promote oral/dental health. The development and commercialization of these innovative oral/dental health products will establish Integra Medical Inc. as a leading provider of probiotic therapeutics and help improve the overall health of countless Canadians and others worldwide.

口腔/牙齿疾病——主要由细菌和真菌病原体感染引起——已被证明对许多全身性疾病的发展有重大贡献。尽管过去十年口腔保健产品的支出有所增加，而且公众对牙科护理标准的认识有所增加，但加拿大、美国和国际上所有年龄段的牙周病/牙龈炎和蛀牙的发病率仍然极高（60%-90%）。除了刷牙、洁牙和使用抗菌产品外，目前保持口腔健康的选择很少。益生菌疗法基于友好细菌干扰并与病原体竞争身体各个部位的空间和营养的概念，以恢复自然微生物群平衡，从而减少炎症、组织损伤和其他负面影响。益生菌正迅速变得越来越受到医疗专业人士的接受和欢迎，用于治疗多种疾病，包括消化道疾病和耳鼻喉感染。位于安大略省伦敦的 Integra Medical Inc. 专注于开发具有科学和临床证明的健康益处的新型益生菌产品。该公司目前有两种口腔护理益生菌产品（LorodentTM 和 KariodentTM）正在进行临床评估，并计划在未来五年内在泌尿科和骨/关节健康等其他领域推出新产品。 Integra 将与范莎学院益生菌领域的领先专家 Peter Cadieux 博士以及来自科学实验室技术文凭课程和应用技术学士（生物技术）学位课程的 Fanshawe 合作学生合作，对从多个临床试验中获得的样本进行严格的科学分析，以评估 Lorodent 和 Kariodent 促进口腔/牙齿健康的功效。这些创新口腔/牙齿健康产品的开发和商业化将使 Integra Medical Inc. 成为益生菌疗法的领先供应商，并帮助改善无数加拿大人和世界各地其他人的整体健康。